PubRank

Gerald L Andriole

Author PubWeight™ 235.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012 24.06
2 Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007 21.18
3 Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008 17.65
4 Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012 11.48
5 The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 11.25
6 Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011 9.13
7 Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011 6.45
8 Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2010 4.84
9 Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 2009 3.76
10 Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009 3.59
11 Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008 3.51
12 A framework for the identification of men at increased risk for prostate cancer. J Urol 2009 3.07
13 Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2005 3.01
14 Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011 2.51
15 Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006 2.48
16 PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010 2.33
17 Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology 2011 2.28
18 Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009 2.20
19 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003 2.16
20 Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 2009 1.94
21 Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2010 1.91
22 Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A 2009 1.81
23 RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate 2007 1.74
24 Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 2013 1.66
25 Risk-based prostate cancer screening. Eur Urol 2011 1.64
26 Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev 2012 1.63
27 The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006 1.63
28 A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 2005 1.63
29 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med 2013 1.60
30 The MAPP research network: design, patient characterization and operations. BMC Urol 2014 1.56
31 Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 2011 1.54
32 The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol 2014 1.47
33 Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011 1.46
34 Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology 2009 1.45
35 Use of gelatin matrix to rapidly repair diaphragmatic injury during laparoscopy. Urology 2002 1.45
36 Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology 2013 1.45
37 Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol 2011 1.44
38 Three-Dimensional (3D) Vision: Does It Improve Laparoscopic Skills? An Assessment of a 3D Head-Mounted Visualization System. Rev Urol 2005 1.41
39 Pure laparoscopic radical heminephrectomy and partial isthmusectomy for renal cell carcinoma in a horseshoe kidney: case report and technical considerations. Urology 2005 1.39
40 Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003 1.31
41 Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007 1.30
42 Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst 2010 1.29
43 2D versus 3D visualization: impact on laparoscopic proficiency using the fundamentals of laparoscopic surgery skill set. J Laparoendosc Adv Surg Tech A 2012 1.29
44 Laparoscopic partial nephrectomy for renal masses: effect of tumor location. Urology 2006 1.27
45 Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst 2012 1.27
46 Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010 1.23
47 Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 2007 1.18
48 Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet 2011 1.17
49 Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008 1.17
50 Screening for prostate cancer. BMJ 2010 1.14
51 Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int 2007 1.13
52 Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 2008 1.13
53 Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr 2012 1.11
54 Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol 2011 1.11
55 Prostate-specific antigen-based screening: controversy and guidelines. BMC Med 2015 1.08
56 Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 2006 1.07
57 Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int 2008 1.07
58 Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome. J Urol 2012 1.04
59 Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol 2009 1.03
60 Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr 2007 1.02
61 Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet 2009 1.01
62 The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int 2013 1.01
63 Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev 2010 0.99
64 Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007 0.98
65 Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004 0.97
66 Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. J Urol 2012 0.97
67 TNF polymorphisms and prostate cancer risk. Prostate 2008 0.95
68 Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet 2011 0.94
69 The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005 0.93
70 Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 2008 0.93
71 Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs 2006 0.93
72 Changes in symptoms during urologic chronic pelvic pain syndrome symptom flares: findings from one site of the MAPP Research Network. Neurourol Urodyn 2013 0.92
73 Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 2007 0.90
74 Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int 2012 0.87
75 Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int 2014 0.87
76 Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003 0.87
77 Renal hypothermia achieved by retrograde endoscopic cold saline perfusion: technique and initial clinical application. Urology 2003 0.87
78 Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology 2011 0.86
79 Managing the local complications of locally advanced prostate cancer. Curr Urol Rep 2007 0.86
80 Ascertaining cause of death among men in the prostate cancer intervention versus observation trial. Clin Trials 2013 0.85
81 5α-reductase inhibitors: preventing the treatable. Eur Urol 2012 0.84
82 Prostate cancer diagnosis. Mo Med 2010 0.84
83 Prevention of benign prostatic hyperplasia disease. J Urol 2006 0.84
84 Laparoscopic partial nephrectomy with a novel electrosurgical snare in a porcine model. J Endourol 2002 0.83
85 Prostate cancer chemoprevention. Semin Oncol 2013 0.83
86 Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer 2002 0.83
87 The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol 2002 0.83
88 Chemoprevention of prostate cancer. Annu Rev Med 2013 0.83
89 Single-setting bilateral laparoscopic renal surgery: assessment of single-stage procedure. Urology 2005 0.82
90 Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol 2012 0.82
91 Urological chronic pelvic pain syndrome symptom flares: characterisation of the full range of flares at two sites in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. BJU Int 2014 0.81
92 Prostate cancer: to screen or not to screen? Urol Clin North Am 2010 0.80
93 The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Urol Oncol 2012 0.79
94 Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy 2011 0.79
95 High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? J Natl Cancer Inst 2007 0.79
96 The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial. J Urol 2012 0.79
97 Prostate-specific antigen-based risk assessment in younger men. Eur Urol 2011 0.78
98 Application of a fixed retractor system to facilitate laparoscopic radical prostatectomy. J Urol 2004 0.78
99 Laparoscopic prostatectomy for prostate cancer: continued role in urology. Surg Oncol Clin N Am 2012 0.78
100 Prospective randomized comparison of cutting and dilating disposable trocars for access during laparoscopic renal surgery. JSLS 2007 0.77
101 Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty. J Urol 2005 0.77
102 Physical activity and benign prostatic hyperplasia-related outcomes and nocturia. Med Sci Sports Exerc 2015 0.77
103 Update on chemoprevention for prostate cancer. Curr Opin Urol 2010 0.77
104 Bad habits may be hard to break. Eur Urol 2012 0.76
105 Improving prostate-specific antigen screening. J Clin Oncol 2010 0.75
106 Making an imperfect marker better. Eur Urol 2010 0.75
107 Prostate cancer: improvements in risk stratification of prostate cancer. Nat Rev Urol 2013 0.75
108 Sexually transmitted diseases among users of erectile dysfunction drugs. Ann Intern Med 2010 0.75
109 Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50". Cancer 2010 0.75
110 Active surveillance for prostate cancer: barriers to widespread adoption. Eur Urol 2012 0.75
111 Editorial comment. Urology 2013 0.75
112 Editorial comment. Urology 2013 0.75
113 Are changes in US practices for androgen deprivation therapy financially motivated? Nat Clin Pract Urol 2008 0.75
114 Improving the early detection of prostate cancer: a balancing act. Oncology (Williston Park) 2014 0.75
115 Prostate cancer chemoprevention with 5α-reductase inhibitors. Urol Oncol 2012 0.75
116 Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol 2006 0.75
117 Urology--2007 & beyond. Mo Med 2007 0.75
118 Fifth joint meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association. Int J Urol 2010 0.75
119 Brain signature and functional impact of centralized pain: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Network Study. Pain 2017 0.75